Co-administration of erythropoietin and iron complex improves late-phase liver regeneration
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Erythropoietin and iron have individually shown beneficial effects on early-phase liver regeneration following partial hepatectomy (PHx); however, there are limited data on the combined effect on late-phase liver regeneration after PHx. Here we examined combined effects of recombinant human erythropoietin (rhEPO, 3,000 IU/kg) and iron isomaltoside (IIM, 40 mg/kg) on late-phase liver regeneration following PHx and investigated the possible underlying mechanism. Rats administrated with rhEPO showed significantly higher liver mass restoration, interleukin-6 (IL-6, a hepatocyte mitogen) levels, and Ki-67-positive hepatocytes on day 7 after PHx than saline-treated controls. These beneficial effects were further enhanced on days 7 and 14 by co-treatment with IIM. This combination also significantly improved liver function indices, such as increased albumin production and decreased bilirubin levels, but did not alter serum levels of toxic parameters, such as aspartate transaminase and alanine transaminase. This study demonstrates that the combination of rhEPO and IIM synergistically improves late-phase liver regeneration and function after PHx, probably by promoting IL-6-mediated hepatocyte proliferation without adverse effects. Thus, this combination treatment can be a potential therapeutic strategy for patients undergoing resection for hepatic malignancies.
Abstract
Erythropoietin and iron have individually shown beneficial effects on early-phase liver regeneration following partial hepatectomy (PHx); however, there are limited data on the combined effect on late-phase liver regeneration after PHx. Here we examined combined effects of recombinant human erythropoietin (rhEPO, 3,000 IU/kg) and iron isomaltoside (IIM, 40 mg/kg) on late-phase liver regeneration following PHx and investigated the possible underlying mechanism. Rats administrated with rhEPO showed significantly higher liver mass restoration, interleukin-6 (IL-6, a hepatocyte mitogen) levels, and Ki-67-positive hepatocytes on day 7 after PHx than saline-treated controls. These beneficial effects were further enhanced on days 7 and 14 by co-treatment with IIM. This combination also significantly improved liver function indices, such as increased albumin production and decreased bilirubin levels, but did not alter serum levels of toxic parameters, such as aspartate transaminase and alanine transaminase. This study demonstrates that the combination of rhEPO and IIM synergistically improves late-phase liver regeneration and function after PHx, probably by promoting IL-6-mediated hepatocyte proliferation without adverse effects. Thus, this combination treatment can be a potential therapeutic strategy for patients undergoing resection for hepatic malignancies.
참고문헌 (30)
- Belghiti J, "Seven hundred forty-seven hepatectomies in the 1990s : an update to evaluate the actual risk of liver resection", J Am Coll Surg, 191, pp.38~46 (2000)
- Garcea G, "Liver failure after major hepatic resection", J Hepatobiliary Pancreat Surg, 16, pp.145~155 (2009)
- Schmeding M, "Erythropoietin promotes hepatic regeneration after extended liver resection in rats", J Gastroenterol Hepatol, 23, pp.1125~1131 (2008)
- Greif F, "Dual effect of erythropoietin on liver protection and regeneration after subtotal hepatectomy in rats", Liver Transpl, 16, pp.631~638 (2010)
- Bockhorn M, "Erythropoietin treatment improves liver regeneration and survival in rat models of extended liver resection and living donor liver transplantation", Transplantation, 86, pp.1578~1585 (2008)
- An S, "Accelerated proliferation of hepatocytes in rats with iron overload after partial hepatectomy", Histochem Cell Biol, 138, pp.773~786 (2012)
- Seehofer D, "Synergistic effect of erythropoietin but not G-CSF in combination with curcumin on impaired liver regeneration in rats", Langenbecks Arch Surg, 393, pp.325~332 (2008)
- Michalopoulos GK, "Liver regeneration", Science, 276, pp.60~66 (1997)
- Tao Y, "Liver regeneration : Analysis of the main relevant signaling molecules", Mediators Inflamm, 2017, pp.4256352~ (2017)
- Jelkmann W, "Molecular biology of erythropoietin", Intern Med, 43, pp.649~659 (2004)
- Ghezzi P, "Erythropoietin as an antiapoptotic, tissue-protective cytokine", Cell Death Differ, 11, pp.S37~44 (2004)
- Fan H, "A link between ferritin gene expression and ribonucleotide reductase R2protein, as demonstrated by retroviral vector mediated stable expression of R2 cDNA", FEBS Lett, 382, pp.145~148 (1996)
- Kuma S, "Effect of human recombinant interleukin-6 on the proliferation of mouse hepatocytes in the primary culture", Immunobiology, 180, pp.235~242 (1990)
- Kang LI, "Signals and cells involved in regulating liver regeneration", Cells, 1, pp.1261~1292 (2012)
- Huh CG, "Hepatocyte growth factor", c-met signaling pathway is required for efficient liver regeneration and repair, 2004, pp.101, 4477~4482
- Yokoyama Y, "Mechanisms of hepatic regeneration following portal vein embolization and partial hepatectomy : a review", World J Surg, 31, pp.367~374 (2007)
- Fisette A, "High-dose insulin therapy reduces postoperative liver dysfunction and complications in liver resection patients through reduced apoptosis and altered inflammation", J Clin Endocrinol Metab, 97, pp.217~226 (2012)
- Pawlik TM, "Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma", Arch Surg, 140, pp.450~457 (2005)
- Mollbrink A, "Iron-regulatory gene expression during liver regeneration", Scand J Gastroenterol, 47, pp.591~600 (2012)
- Pachówka M, "The role of IL-6 during the late phase of liver regeneration", Ann Transplant, 13, pp.15~19 (2008)
- Cui Y, "Hepaticuptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6", J Biol Chem, 276, pp.9626~9630 (2001)
- Lehmann K, "Liver failure after extended hepatectomy in mice is mediated by a p21-dependent barrier to liver regeneration", Gastroenterology, 143, pp.1609~1619 (2012)
- Koniaris LG, "Liver regeneration", J Am Coll Surg, 197, pp.634~659 (2003)
- Balleari E, "Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes", Leuk Res, 35, pp.1472~1476 (2011)
- Ehrenreich H, "Recombinant human erythropoietin in the treatment of acute ischemic stroke", Stroke, 40, pp.e647~656 (2009)
- Danielson J, "Structure, chemistry, and pharmacokinetics of intravenous iron agents", Am Soc Nephrol, 15, pp.S93~S98 (2004)
- Wikström B, "Iron isomaltoside 1000 : a new intravenous iron for treating iron deficiency in chronic kidney disease", J Nephrol, 24, pp.589~596 (2011)
- Kalra PA, "Efficacy and safety of iron isomaltoside(Monofer(Ⓡ))in the management of patients with iron deficiency anemia", Int J Nephrol Renovasc Dis, 9, pp.53~64 (2016)
- Higgins GM, "Experimental pathology of the liver. 1. Restoration of the liver of the white rat following partial surgical removal", Arch Pathol, 12, pp.186~202 (1931)
- Meier M, "Liver regeneration is dependent on the extent of hepatectomy", J Surg Res, 205, pp.76~84 (2016)